NeuroMetrix initiated at H.C. Wainwright

NeuroMetrix initiated with a Buy at H.C. Wainwright. H.C. Wainwright analyst Andrew Fein initiated NeuroMetrix with a Buy rating and $5 price target, stating that he sees “plenty of room for the stock to appreciate” and believes that the recent launch of a new generation of Quell technology could facilitate market adoption given its smarter design, a 50% smaller size, and a better app. He also thinks the environment for addressing the opioid crisis, and a pressing need to limit opioid use while seeking alternative pain management options, bodes well for Quell uptake, Fein tells investors.

https://thefly.com/landingPageNews.php?id=2841163